Share Email Print

Proceedings Paper

Clinical photodynamic therapy using Russian photosensitizers Photoheme and Photosense: six-year experience
Author(s): Eugeny Ph. Stranadko; Vladimir M. Meshkov; U. M. Koraboyev; Michail V. Riabov
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

Background and objective Unsatisfactory results of traditional treatment of malignant tumors force oncologists to search new therapeutic modalities. Photodynamic therapy (PDT) is one ofthe promising and intensively developing techniques in cancer treatment. Materials and methods The results of application of photodynamic therapy for treatment of malignant tumors of various localizations were assessed. In 1992 - 1998 more than 1270 malignant tumors in 308 patients have been treated with PDT. Most of the patients have been taken into PDT for tumor recurrences or mtradermal metastases after surgery, gamma-therapy or combined treatment. Russian photosensitizers Photoheme and Photosense were used. Results Up to date we obtain the follow-up data in term from 2 months to 6 years. Therapeutic effect took place in 94.7% of cases. including complete tumor resorption in 55 .5% and partial resorption in 39.2% of cases. Conclusion The results of PDT application for treating malignant tumors allow one to estimate PDT as adequate technique. In some tumor localizations PDT may become optional technique.

Paper Details

Date Published: 30 December 1999
PDF: 7 pages
Proc. SPIE 4059, Laser Use in Oncology II, (30 December 1999); doi: 10.1117/12.375269
Show Author Affiliations
Eugeny Ph. Stranadko, State Research Ctr. for Laser Medicine (Russia)
Vladimir M. Meshkov, Ctr. for New Medical Technologies (Russia)
U. M. Koraboyev, State Research Ctr. for Laser Medicine (Russia)
Michail V. Riabov, State Research Ctr. for Laser Medicine (Russia)

Published in SPIE Proceedings Vol. 4059:
Laser Use in Oncology II
Andrei V. Ivanov; Mishik A. Kazaryan, Editor(s)

© SPIE. Terms of Use
Back to Top
Sign in to read the full article
Create a free SPIE account to get access to
premium articles and original research
Forgot your username?